Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.

about

Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.

Item

http://www.wikidata.org/entity/Q41092832

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Increased efficacy of intermed ...... olish lymphoma research group.

@en

type

Item

label

Increased efficacy of intermed ...... olish lymphoma research group.

@en

prefLabel

Increased efficacy of intermed ...... olish lymphoma research group.

@en

P1476

Increased efficacy of intermed ...... olish lymphoma research group.

@en

P2093

Agnieszka Wierzbowska

http://www.w3.org/2001/XMLSchema#string

Jerzy Holowiecki

http://www.w3.org/2001/XMLSchema#string

Joanna Drozd-Sokolowska

http://www.w3.org/2001/XMLSchema#string

Malgorzata Sobczyk-Kruszelnicka

http://www.w3.org/2001/XMLSchema#string

Maria Sadus-Wojciechowska

http://www.w3.org/2001/XMLSchema#string

Mateusz Nowicki

http://www.w3.org/2001/XMLSchema#string

Sebastian Giebel

http://www.w3.org/2001/XMLSchema#string

Tomasz Czerw

http://www.w3.org/2001/XMLSchema#string

Wlodzimierz Mendrek

http://www.w3.org/2001/XMLSchema#string

P2860

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the

Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.

P304

263-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-015-2557-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jacek Najda

K Halaburda

P577

2015-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26611854

http://www.w3.org/2001/XMLSchema#string